Davos is collaborating with the Moffitt Cancer Institute in Florida on the development of tocotrienol as a sole therapeutic agent for Pancreatic Cancer. 

Davos is collaborating with the Li Ka Shing Faculty of Medicine, The University of Hong Kong on the development of tocotrienol as a preventive and therapeutic agent for Prostate Cancer. 

Davos is collaborating with the Australian Prostate Cancer Research Centre-Queensland Institute of Health and Biomedical Innovation (IHBI) on the development of tocotrienol as a preventive and therapeutic agent for Prostate Cancer. 

Davos is collaborating with the Tokyo Medical and Dental University on the development of tocotrienol as a therapeutic agent for improving Cardiovascular Health. 

Davos is collaborating with the University of Nottingham (Malaysia campus) on the development of tocotrienol as a therapeutic agent for Lung Cancer. 

Davos is collaborating with the International Medical University (IMU) on the development of tocotrienol as an anti-inflammatory agent for Rheumatoid Arthritis.